Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy & Safety of an Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide written informed consent to participate in the study;~* Willing and able to comply with all study requirements and instructions of the site study staff;~* Male or female, 40 years to 85 years old (inclusive);~* Must be ambulatory;~* Index knee must be symptomatic for greater than 6 months with a clinical diagnosis of OA and supported by radiological evidence (Kellgren Lawrence Grade II, III, or IV) read by a central reader;~* WOMAC 5-point Likert pain subscale \<1.5 in the contralateral knee;~* Moderate to moderately-severe OA pain in the index knee (rating of at least 1.5 on the WOMAC Index 3.1 5-point Likert Pain Subscale);~* Moderate to moderately-severe OA pain in the index knee (even if chronic doses of nonsteroidal anti-inflammatory drug (NSAID), which have not changed in the 4 weeks prior to screening, have been/are being used);~* Ability to discontinue NSAID use at Screening visit and/or 72 hours prior to the Baseline visit and for the duration of the clinical study (low dose Aspirin is allowed during the study);~* No analgesia (including acetaminophen \[paracetamol\]) taken 24 hours prior to an efficacy measure;~* No known clinically significant liver abnormality (e.g. cirrhosis, transplant, etc.).~Exclusion Criteria:~* As a result of medical review and screening investigation, the Principal Investigator considers the patient unfit for the study~* A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion)~* A history of allergic reactions to excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate)~* Presence of tense effusions~* Inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis or joint replacement in the affected knee, as assessed locally by the Principal Investigator~* Isolated patella femoral syndrome, also known as chondromalacia~* Any other disease or condition interfering with the free use and evaluation of the index knee for the duration of the trial (e.g. cancer, congenital defects, spine osteoarthritis)~* Major injury to the index knee within the 12 months prior to screening~* Severe hip osteoarthritis ipsilateral to the index knee~* Any pain that could interfere with the assessment of index knee pain (e.g. pain in any other part of the lower extremities, pain radiating to the knee)~* Any pharmacological or non-pharmacological treatment targeting OA started or changed during the 4 weeks prior to randomization or likely to be changed during the duration of the study~* Pregnancy or planning to become pregnant during the study.~* Use of the following medications:~* No IA injected pain medications in the study knee during the study~* No analgesics containing opioids.~* NSAIDs are not permitted during the study; acetaminophen is available as a rescue medication during the study from the provided supply.~* No topical treatment on osteoarthritis index knee during the study~* No significant anticoagulant therapy (e.g. Heparin or Lovenox) during the study (treatment such as low dose Aspirin and Plavix are allowed)~* No systemic treatments that may interfere with safety or efficacy assessments during the study~* No immunosuppressants~* No use of corticosteroids~* No human albumin treatment in the 3 months before randomization or throughout the duration of the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- AMPION™ 4 mL dose (Type: EXPERIMENTAL): 4 mL injection of Ampion
- Placebo 4 mL dose (Type: PLACEBO_COMPARATOR): 4 mL Injection of Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).